CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
85.07
1.37%
Market Trading Hours* (UTC) Opens on Friday at 07:00

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.32
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022102 %
Charges from full value of position ($-4.20)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022102%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000121 %
Charges from full value of position ($-0.02)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000121%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Sanofi SA ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 86.25
Open* 85.59
1-Year Change* -16.48%
Day's Range* 84.98 - 85.95
52 wk Range 80.60-105.18
Average Volume (10 days) 1.20M
Average Volume (3 months) 34.27M
Market Cap 119.76B
P/E Ratio 13.13
Shares Outstanding 1.25B
Revenue 45.70B
EPS 7.21
Dividend (Yield %) 3.75964
Beta 0.50
Next Earnings Date Feb 1, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 17, 2024 86.25 0.40 0.47% 85.85 86.97 85.85
Apr 16, 2024 86.59 -0.36 -0.41% 86.95 87.13 85.99
Apr 15, 2024 87.14 0.93 1.08% 86.21 88.00 86.21
Apr 12, 2024 86.30 -0.35 -0.40% 86.65 86.94 85.97
Apr 11, 2024 86.55 -1.14 -1.30% 87.69 88.36 86.26
Apr 10, 2024 87.93 0.34 0.39% 87.59 88.33 87.13
Apr 9, 2024 87.02 1.04 1.21% 85.98 87.09 85.97
Apr 8, 2024 86.90 -0.27 -0.31% 87.17 87.52 86.85
Apr 5, 2024 87.25 -0.35 -0.40% 87.60 87.73 86.58
Apr 4, 2024 88.67 0.43 0.49% 88.24 89.74 88.24
Apr 3, 2024 88.74 0.32 0.36% 88.42 88.88 88.14
Apr 2, 2024 88.59 -0.21 -0.24% 88.80 90.76 88.56
Mar 28, 2024 90.94 0.00 0.00% 90.94 91.69 90.57
Mar 27, 2024 91.61 1.45 1.61% 90.16 91.87 90.16
Mar 26, 2024 91.26 1.40 1.56% 89.86 91.28 89.77
Mar 25, 2024 89.49 0.99 1.12% 88.50 89.57 88.17
Mar 22, 2024 88.29 0.79 0.90% 87.50 89.14 86.75
Mar 21, 2024 87.54 -0.20 -0.23% 87.74 87.95 86.66
Mar 20, 2024 87.42 0.29 0.33% 87.13 87.58 86.85
Mar 19, 2024 87.16 -0.73 -0.83% 87.89 87.99 86.74

Sanofi SA Events

Time (UTC) Country Event
Thursday, April 25, 2024

Time (UTC)

05:30

Country

FR

Event

Q1 2024 Sanofi SA Earnings Release
Q1 2024 Sanofi SA Earnings Release

Forecast

-

Previous

-

Time (UTC)

12:30

Country

FR

Event

Q1 2024 Sanofi SA Earnings Call
Q1 2024 Sanofi SA Earnings Call

Forecast

-

Previous

-
Tuesday, April 30, 2024

Time (UTC)

12:30

Country

FR

Event

Sanofi SA Annual Shareholders Meeting
Sanofi SA Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, May 9, 2024

Time (UTC)

12:00

Country

FR

Event

Sanofi SA
Sanofi SA

Forecast

-

Previous

-
Monday, May 13, 2024

Time (UTC)

12:00

Country

FR

Event

Sanofi SA
Sanofi SA

Forecast

-

Previous

-
Thursday, July 25, 2024

Time (UTC)

05:30

Country

FR

Event

Q2 2024 Sanofi SA Earnings Release
Q2 2024 Sanofi SA Earnings Release

Forecast

-

Previous

-

Time (UTC)

12:30

Country

FR

Event

Q2 2024 Sanofi SA Earnings Call
Q2 2024 Sanofi SA Earnings Call

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 45389 39175 37369 37631 35677
Revenue 45389 39175 37369 37631 35677
Cost of Revenue, Total 13695 12255 12159 11979 11435
Gross Profit 31694 26920 25210 25652 24242
Total Operating Expense 34733 31049 23256 34580 31001
Selling/General/Admin. Expenses, Total 10410 9457 9304 9777 9772
Research & Development 6705 5689 5528 6017 5890
Depreciation / Amortization 2140 1681 1774 2262 2264
Unusual Expense (Income) -581 235 777 3966 1696
Other Operating Expenses, Total 2391 1728 1220 817 61
Operating Income 10656 8126 14113 3051 4676
Interest Income (Expense), Net Non-Operating -167 -289 -263 -210 -273
Other, Net -67 -39 -72 -89 2
Net Income Before Taxes 10422 7798 13778 2752 4405
Net Income After Taxes 8416 6240 11971 2631 3924
Minority Interest -113 -56 -36 -31 -104
Equity In Affiliates 68 39 359 255 499
Net Income Before Extra. Items 8371 6223 12294 2855 4319
Total Extraordinary Items 0 0 -101 -13
Net Income 8371 6223 12294 2754 4306
Income Available to Common Excl. Extra. Items 8371 6223 12294 2855 4319
Income Available to Common Incl. Extra. Items 8371 6223 12294 2754 4306
Dilution Adjustment
Diluted Net Income 8371 6223 12294 2754 4306
Diluted Weighted Average Shares 1256.9 1257.9 1260.1 1257.1 1255.2
Diluted EPS Excluding Extraordinary Items 6.66004 4.94713 9.75637 2.2711 3.44089
Dividends per Share - Common Stock Primary Issue 3.56 3.31263 3.2 3.15 3.07
Diluted Normalized EPS 5.79655 5.09663 10.2921 5.28727 4.64452
Interest Expense (Income) - Net Operating -27 4 -7506 -238 -117
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 21545 10863 24594 13138 20795
Revenue 21545 10863 24594 13138 20795
Cost of Revenue, Total 6347 3079 7565 3831 6130
Gross Profit 15198 7784 17029 9307 14665
Total Operating Expense 17223 8400 17767 10414 16966
Selling/General/Admin. Expenses, Total 5182 2607 5539 2644 4953
Research & Development 3193 1563 3559 1736 3147
Depreciation / Amortization 1035 489 1143 460 910
Unusual Expense (Income) 635 343 231 1955 1021
Other Operating Expenses, Total 805 304 -226 -180 788
Operating Income 4322 2463 6827 2724 3829
Interest Income (Expense), Net Non-Operating 4 -7 -62 -51 -135
Net Income Before Taxes 4238 2456 6748 2673 3674
Net Income After Taxes 3508 1997 5237 2072 3179
Minority Interest -26 -14 -60 -3 -53
Equity In Affiliates -52 12 10 7 58
Net Income Before Extra. Items 3430 1995 5187 2076 3184
Net Income 3430 1995 5187 2076 3184
Income Available to Common Excl. Extra. Items 3430 1995 5187 2076 3184
Income Available to Common Incl. Extra. Items 3430 1995 5187 2076 3184
Diluted Net Income 3430 1995 5187 2076 3184
Diluted Weighted Average Shares 1254.5 1249.3 1258.5 1253.5 1255.3
Diluted EPS Excluding Extraordinary Items 2.73416 1.59689 4.12157 1.65616 2.53645
Dividends per Share - Common Stock Primary Issue 0 0 3.56 0 0
Diluted Normalized EPS 3.15315 1.82014 4.26402 2.86513 3.24021
Interest Expense (Income) - Net Operating 26 15 -44 -32 17
Other, Net -88 -17 -20
Total Extraordinary Items
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 34026 30564 33703 28611 24579
Cash and Short Term Investments 13400 11152 14815 9853 7124
Cash 1385 1358 1144 701 661
Cash & Equivalents 11351 8740 12771 8726 6264
Short Term Investments 664 1054 900 426 199
Total Receivables, Net 10746 9787 9953 10083 9345
Accounts Receivable - Trade, Net 8424 7568 7491 7937 7260
Total Inventory 8960 8715 8352 7994 7477
Prepaid Expenses 714 615 525 493 469
Other Current Assets, Total 206 295 58 188 164
Total Assets 126722 120242 114413 112630 111408
Property/Plant/Equipment, Total - Net 11684 11976 10563 11017 9651
Property/Plant/Equipment, Total - Gross 26796 27555 24880 25151 22697
Accumulated Depreciation, Total -15112 -15579 -14317 -14134 -13046
Goodwill, Net 49892 48056 44364 44519 44235
Intangibles, Net 21640 21407 18341 16509 21889
Long Term Investments 2765 2425 2129 5303 5550
Note Receivable - Long Term 452 485 537 521 746
Other Long Term Assets, Total 6263 5329 4776 6150 4758
Total Current Liabilities 23964 21295 19248 20381 17376
Accounts Payable 6813 6180 5295 5313 5041
Accrued Expenses 2158 2126 2042 1978 1989
Notes Payable/Short Term Debt 168 189 285 305 249
Current Port. of LT Debt/Capital Leases 4287 3263 2714 4508 2364
Other Current Liabilities, Total 10538 9537 8912 8277 7733
Total Liabilities 51938 51561 51307 53574 52532
Total Long Term Debt 16761 18962 20676 21118 22071
Long Term Debt 14857 17123 19745 20131 22053
Capital Lease Obligations 1904 1839 931 987 18
Deferred Income Tax 1841 1617 1770 2294 3414
Minority Interest 368 350 146 174 159
Other Liabilities, Total 9004 9337 9467 9607 9512
Total Equity 74784 68681 63106 59056 58876
Common Stock 2522 2527 2518 2508 2495
Additional Paid-In Capital 66859 63545 60511 52049 53106
Treasury Stock - Common -706 -939 -705 -9 -153
Other Equity, Total 6109 3548 782 4508 3428
Total Liabilities & Shareholders’ Equity 126722 120242 114413 112630 111408
Total Common Shares Outstanding 1252.64 1252.54 1250.69 1253.83 1245.45
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 29976 34026
Cash and Short Term Investments 7993 12736
Cash & Equivalents 7993 12736
Total Receivables, Net 8642 8798
Accounts Receivable - Trade, Net 8289 8424
Total Inventory 9970 8960
Other Current Assets, Total 3371 3532
Total Assets 125353 126722
Property/Plant/Equipment, Total - Net 11527 11684
Goodwill, Net 49243 49892
Intangibles, Net 24590 21640
Long Term Investments 2550 2765
Note Receivable - Long Term 447 452
Other Long Term Assets, Total 7020 6263
Total Current Liabilities 24760 23964
Accounts Payable 7365 6813
Notes Payable/Short Term Debt 133 168
Current Port. of LT Debt/Capital Leases 4780 4287
Other Current Liabilities, Total 12482 12696
Total Liabilities 52724 51938
Total Long Term Debt 16080 16761
Long Term Debt 14241 14857
Capital Lease Obligations 1839 1904
Deferred Income Tax 1950 1841
Minority Interest 318 368
Other Liabilities, Total 9616 9004
Total Equity 72629 74784
Common Stock 2525 2522
Additional Paid-In Capital 140 66859
Retained Earnings (Accumulated Deficit) 65694
Treasury Stock - Common -957 -706
Other Equity, Total 5227 6109
Total Liabilities & Shareholders’ Equity 125353 126722
Total Common Shares Outstanding 1251.49 1252.64
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 8371 6223 12294 2754 4306
Cash From Operating Activities 10526 10522 7418 7715 5547
Cash From Operating Activities 3420 3351 3671 7445 4279
Deferred Taxes -578 -356 -221 -1772 -727
Non-Cash Items 20 -105 -8001 -293 -1031
Cash Taxes Paid 2452 1280 2051 1695 2058
Cash Interest Paid 380 334 315 379 412
Changes in Working Capital -707 1409 -325 -419 -1280
Cash From Investing Activities -2075 -7298 3619 -1029 -12872
Capital Expenditures -2201 -2043 -2083 -1787 -1977
Other Investing Cash Flow Items, Total 126 -5255 5702 758 -10895
Cash From Financing Activities -5821 -7056 -6485 -4193 3934
Financing Cash Flow Items -99 -48 -44 -21 -91
Total Cash Dividends Paid -4168 -4008 -3937 -3834 -3773
Issuance (Retirement) of Stock, Net -309 -196 -619 153 -924
Issuance (Retirement) of Debt, Net -1245 -2804 -1885 -491 8722
Foreign Exchange Effects 8 15 -64 9 1
Net Change in Cash 2638 -3817 4488 2502 -3390
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 8371 3184
Cash From Operating Activities 10526 3825
Cash From Operating Activities 3420 1820
Deferred Taxes -578 -404
Non-Cash Items 20 267
Cash Taxes Paid 2452 927
Cash Interest Paid 380 162
Changes in Working Capital -707 -1042
Cash From Investing Activities -2075 -1459
Capital Expenditures -2201 -974
Other Investing Cash Flow Items, Total 126 -485
Cash From Financing Activities -5821 -5605
Financing Cash Flow Items -99 -69
Total Cash Dividends Paid -4168 -4168
Issuance (Retirement) of Stock, Net -309 -320
Issuance (Retirement) of Debt, Net -1245 -1048
Foreign Exchange Effects 8 40
Net Change in Cash 2638 -3199

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sanofi Company profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
Industry: Pharmaceuticals (NEC)

46 Avenue de la Grande Armée
PARIS
ILE-DE-FRANCE 75017
FR

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

XRP/USD

0.49 Price
-2.050% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

2,965.66 Price
+0.460% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,404.55 Price
+1.920% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0108%
Overnight fee time 21:00 (UTC)
Spread 0.39

US100

17,131.40 Price
-2.020% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading